Question 1

What is the main difference between CT-388 and Tirzepatide?

Accepted Answer

Both CT-388 and Tirzepatide are categorized under Metabolic, but they differ in evidence strength. CT-388 has Moderate evidence (8 sources), while Tirzepatide has High evidence (42 sources).

Question 2

Which has more clinical evidence, CT-388 or Tirzepatide?

Accepted Answer

Tirzepatide has more clinical evidence with 38 human studies compared to 6 for CT-388. Overall, Tirzepatide has High evidence strength while CT-388 has Moderate.

Question 3

Are CT-388 and Tirzepatide FDA approved?

Accepted Answer

CT-388 has moderate clinical evidence from human studies, though its regulatory status varies. Tirzepatide has high-level clinical evidence, indicating FDA-approved or Phase 3 validated status. Always verify current regulatory status with official sources.

Question 4

Can CT-388 and Tirzepatide be combined?

Accepted Answer

Based on available data, these peptides are considered not recommended for combination. Both are dual GLP-1/GIP receptor agonists with overlapping mechanisms. Combining would duplicate effects and increase risk of severe GI adverse events. No clinical rationale for combination. No combination has been validated in controlled human clinical trials.

CT-388 vs Tirzepatide

CT-388

Tirzepatide

Overview

Evidence Comparison

Key Differences

Summary

View Full Dossiers

Stay Updated on Peptide Comparisons

Aspect	CT-388	Tirzepatide
Evidence Level	Moderate	High
Human Studies	6	38
Preclinical Studies	2	4
Total Sources	8	42

Aspect	CT-388	Tirzepatide
Category	Metabolic	Metabolic
Evidence Strength	Moderate	High
Total Sources	8	42
Human Studies	6	38